NO20110429L - Polypeptider og nukleinsyre-DNA for anvendelse innen medisin - Google Patents

Polypeptider og nukleinsyre-DNA for anvendelse innen medisin

Info

Publication number
NO20110429L
NO20110429L NO20110429A NO20110429A NO20110429L NO 20110429 L NO20110429 L NO 20110429L NO 20110429 A NO20110429 A NO 20110429A NO 20110429 A NO20110429 A NO 20110429A NO 20110429 L NO20110429 L NO 20110429L
Authority
NO
Norway
Prior art keywords
polypeptides
medicine
nucleic acid
acid dna
cancer
Prior art date
Application number
NO20110429A
Other languages
English (en)
Other versions
NO342257B1 (no
Inventor
Jon Amund Eriksen
Gustav Gaudernack
Stein Saeboe-Larssen
Mona Moller
Original Assignee
Gemvax As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9905720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20110429(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20110429L publication Critical patent/NO20110429L/no
Application filed by Gemvax As filed Critical Gemvax As
Priority to NO20110429A priority Critical patent/NO342257B1/no
Publication of NO342257B1 publication Critical patent/NO342257B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20110429A 2000-12-22 2011-03-21 Polypeptider, nukleinsyre-DNA og vektorer for anvendelse som et medikament i behandling av cancer NO342257B1 (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20110429A NO342257B1 (no) 2000-12-22 2011-03-21 Polypeptider, nukleinsyre-DNA og vektorer for anvendelse som et medikament i behandling av cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0031430.2A GB0031430D0 (en) 2000-12-22 2000-12-22 Polypeptides
PCT/NO2001/000498 WO2002051994A2 (en) 2000-12-22 2001-12-18 Polypeptides
NO20110429A NO342257B1 (no) 2000-12-22 2011-03-21 Polypeptider, nukleinsyre-DNA og vektorer for anvendelse som et medikament i behandling av cancer

Publications (2)

Publication Number Publication Date
NO20110429L true NO20110429L (no) 2003-08-21
NO342257B1 NO342257B1 (no) 2018-04-30

Family

ID=9905720

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20032818A NO332137B1 (no) 2000-12-22 2003-06-19 Polypeptid, nukleinsyre, T-lymfocytt og vektor for anvendelse innen medisin samt farmasoytisk sammensetning omfattende nevnte polypeptid.
NO20110429A NO342257B1 (no) 2000-12-22 2011-03-21 Polypeptider, nukleinsyre-DNA og vektorer for anvendelse som et medikament i behandling av cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20032818A NO332137B1 (no) 2000-12-22 2003-06-19 Polypeptid, nukleinsyre, T-lymfocytt og vektor for anvendelse innen medisin samt farmasoytisk sammensetning omfattende nevnte polypeptid.

Country Status (14)

Country Link
US (4) US7078416B2 (no)
EP (3) EP1862544B2 (no)
JP (3) JP2004522433A (no)
AT (2) ATE550426T1 (no)
AU (3) AU2002216477B2 (no)
CA (2) CA2432971C (no)
CY (2) CY1106564T1 (no)
DE (1) DE60127715T2 (no)
DK (3) DK2361978T3 (no)
ES (2) ES2382821T3 (no)
GB (1) GB0031430D0 (no)
NO (2) NO332137B1 (no)
PT (2) PT1862544E (no)
WO (1) WO2002051994A2 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US7388071B2 (en) * 2000-02-15 2008-06-17 The Regents Of The University Of California Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
ES2676503T3 (es) * 2002-12-16 2018-07-20 Globeimmune, Inc. Vacunas basadas en levadura como inmunoterapia
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
WO2004111075A2 (en) 2003-03-05 2004-12-23 Dendreon Corporation Alternative reading frame polypeptides for treatment
EP2460533A3 (en) 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
WO2018145020A1 (en) 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
CA3065325A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
IL133830A0 (en) 1997-07-01 2001-04-30 Cambia Biosystems Llc Vertebrate tolomerase genes and proteins and uses thereof
WO1999050932A1 (fr) * 1998-03-31 1999-10-07 Matsushita Electric Industrial Co., Ltd. Antenne et televiseur numerique
WO1999050392A1 (en) * 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
EP1171612A2 (en) * 1999-04-09 2002-01-16 Biomira, Inc. Telomerase-specific cancer vaccine
AU5047800A (en) 1999-05-28 2000-12-18 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides

Also Published As

Publication number Publication date
DK1352056T3 (da) 2007-05-29
AU2002216477C1 (en) 2002-07-08
ATE550426T1 (de) 2012-04-15
AU2002216477B2 (en) 2007-05-24
NO342257B1 (no) 2018-04-30
DE60127715D1 (de) 2007-05-16
AU2007211889B2 (en) 2009-11-19
JP2004522433A (ja) 2004-07-29
CY1112735T1 (el) 2016-02-10
EP1352056A2 (en) 2003-10-15
AU2007211889B8 (en) 2009-12-10
GB0031430D0 (en) 2001-02-07
DK2361978T3 (en) 2016-01-25
US20080187551A1 (en) 2008-08-07
PT1352056E (pt) 2007-05-31
WO2002051994A3 (en) 2002-12-27
ES2280311T3 (es) 2007-09-16
NO20032818D0 (no) 2003-06-19
EP2361978B1 (en) 2015-10-14
JP2014138587A (ja) 2014-07-31
PT1862544E (pt) 2012-05-07
EP1862544A1 (en) 2007-12-05
US8193326B2 (en) 2012-06-05
ES2382821T3 (es) 2012-06-13
EP1862544B1 (en) 2012-03-21
AU2010200620B2 (en) 2012-11-01
US7375117B2 (en) 2008-05-20
JP2012080883A (ja) 2012-04-26
DK1862544T3 (da) 2012-07-09
CA2432971A1 (en) 2002-07-04
AU2010200620A1 (en) 2010-03-11
US7078416B2 (en) 2006-07-18
AU2007211889C1 (en) 2010-06-10
WO2002051994A8 (en) 2003-03-06
EP1352056B1 (en) 2007-04-04
NO20032818L (no) 2003-08-21
US20060194731A1 (en) 2006-08-31
AU2007211889A1 (en) 2007-09-13
CA2782510C (en) 2014-07-15
EP1862544B2 (en) 2016-03-09
US20040072759A1 (en) 2004-04-15
DE60127715T2 (de) 2007-12-27
CA2782510A1 (en) 2002-07-04
CY1106564T1 (el) 2012-01-25
ATE358716T1 (de) 2007-04-15
US20120269858A1 (en) 2012-10-25
CA2432971C (en) 2012-09-04
EP2361978A1 (en) 2011-08-31
WO2002051994A2 (en) 2002-07-04
NO332137B1 (no) 2012-07-02

Similar Documents

Publication Publication Date Title
NO20110429L (no) Polypeptider og nukleinsyre-DNA for anvendelse innen medisin
MX344216B (es) Productos geneticos expresados de forma diferencial en tumores y su uso.
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
HUP0105303A2 (en) Her-2/neu fusion proteins
ATE386800T1 (de) Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
DE60035337D1 (de) Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoide Tumorzellen, herbeiführen oder bewirken
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
ATE521702T1 (de) Krebsantigene und deren nutzung
WO2005026205A3 (de) Differentiell in tumoren exprimierte genprodukte und deren verwendung
HUP0100267A2 (hu) Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények
RS20050577A (en) Compositions and methods for treating cancer using igsf9 and liv-1
HUP0400703A2 (hu) Csökkentett immunogenitású módosított eritropoietin (EPO)
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
WO2003093298A3 (en) Immunogenic peptides
DE60135232D1 (de) Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
FR2813606B1 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen
TW200518770A (en) Cyclic nucleotide-specific phosphodiesterases from leishmania and uses thereof
WO2004044126A3 (en) Novel proteins and their uses
AR045521A1 (es) Promotor del gen de fatp5 humano y usos
TH55539B (th) เพปไทด์ที่เป็นแอนติเจน

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees